# FASTRACK II (NCT02613819)

> Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02613819
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Trans Tasman Radiation Oncology Group
- Conditions: Renal Cell Carcinoma
- Interventions: SABR
- Enrollment: 71
- Primary outcome: Activity and efficacy of SABR measured by Freedom from local progression assessed by RECIST Criteria

## Commentary we found

- X threads: 63
- YouTube: 3
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=fastrack-ii-nct02613819

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02613819", "email": "<work email>"}; the inbox owner confirms by the emailed link.